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ABSTRACT
Introduction: The present post hoc analysis
was designed to evaluate health-related quality
of life (HRQoL) using the 36-item Short Form
Health Status Survey (SF-36) during an 8-week
trial of sodium oxybate (SXB).
Methods: SF-36 was assessed in a phase 3
placebo-controlled trial in patients with
narcolepsy (N = 228) randomized to placebo or
SXB in doses of 4.5, 6, or 9 g nightly for 8 weeks.
Changes from baseline in SF-36 (last
observation carried forward) were compared
between SXB and placebo, and effect sizes (ES)
were estimated.
Results: Baseline SF-36 values were lower than
normative values for the US general population.
After 8 weeks of treatment, mean (±standard
deviation) improvement from baseline on the
Physical Component Summary (PCS) was
significantly greater with SXB 9 g/night than
placebo (6.3 ± 9.1 vs. 1.5 ± 6.2; p = 0.005), with
moderate ES; no significant difference was found
between the SXB and placebo groups on the
Mental Component Summary. SXB 9 g/night
resulted in significantly (p\0.05) greater
improvements than placebo in Physical
Functioning (4.4 ± 9.2 vs. 1.0 ± 8.0), General
Health (GH; 3.1 ± 7.0 vs. 0.4 ± 6.8), and Social
Functioning (6.8 ± 16.8 vs. 1.1 ± 9.6). All SXB
doses resulted in significant improvement
(p\0.05) relative to placebo for Vitality, with
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Montréal, QC, Canada
Neurol Ther (2016) 5:203–213
DOI 10.1007/s40120-016-0053-5
moderate ES. No significant differences versus
placebo were observed for Role–Physical,
Role–Emotional, or Mental Health domains.
Conclusion: Treatment with SXB was
associated with a dose-dependent
improvement in HRQoL, with the 9-g nightly
dose demonstrating a positive impact on PCS
and individual SF-36 domains of Vitality, GH,
and Physical and Social Functioning.
Trial registration: NCT00049803.
Funding: Jazz Pharmaceuticals.
Keywords: Narcolepsy; Sodium oxybate;
Quality of life; SF-36
INTRODUCTION
Excessive daytime sleepiness (EDS) and cataplexy
(intermittent partial or complete muscle
paralysis) are the most frequently recognized
symptoms of narcolepsy, with hallucinations
upon falling asleep or awakening, sleep
paralysis, and disrupted nighttime sleep
completing the pentad of symptoms associated
with this disease [1, 2].While onset of narcolepsy
generally occurs in childhood or early adulthood
[3, 4], it has consistently been reported that there
can be a delay of 10–15 years between symptom
onset and confirmed diagnosis, with the lack of
recognition by physicians the primary reason for
this delay [5]. This failure to recognize the signs
and symptoms of narcolepsy not only
contributes to reported misdiagnosis [6, 7], but
also delays appropriate treatment, thereby
prolonging the adverse psychosocial impact of
the disease [5].
Health-Related Quality of Life
in Narcolepsy
In addition to the disease-related physical
impairment and the recognized economic
burden of narcolepsy resulting from the direct
costs of higher healthcare resource utilization
and indirect costs associated with
unemployment and lost productivity [8–10],
there is a substantial humanistic burden.
Patients with narcolepsy not only tend to have
a greater prevalence of comorbidities and higher
odds of mortality than those without narcolepsy
[11–13], but health-related quality of life
(HRQoL) has been shown to be reduced across
countries and cultures [14–23]. In particular,
studies using the 36-item Short Form Health
Status Survey (SF-36) to assess HRQoL in patients
with narcolepsy have reported lower scores in
most SF-36 domains compared to the general
population as well as to those experiencing
obstructive sleep apnea, Parkinson’s disease,
and epilepsy [14–16, 18–24].
Because there is no cure for narcolepsy,
treatment occurs over the lifetime of the patient,
with EDS and cataplexy the main targets of most
current therapies [25, 26]. Sodium oxybate (SXB)
is the sodium salt of gamma hydroxybutyrate, an
endogenous metabolite of gamma-aminobutyric
acid; SXB is approved for the treatment of
cataplexy and EDS in narcolepsy [27].
Randomized controlled trials have demonstrated
the efficacy of SXB for reducing EDS and the
frequency of cataplexy attacks in patients with
narcolepsy [28–30]. Improvements in functional
outcomes, assessed using the Functional
Outcomes of Sleep Questionnaire (FOSQ) [31],
have also been suggested [32]. However, no
studies to date have reported on the effects of
SXB on HRQoL using a standard assessment
measure such as the SF-36.
Objective
The purpose of this analysis is to provide data
on the effect of SXB on HRQoL collected during
an 8-week randomized controlled trial.
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METHODS
Design and Patients
This analysis of HRQoL in patients with
narcolepsy treated with SXB is based on data
obtained during an 8-week phase 3 randomized
placebo-controlled trial. Details of the study
design and methods were published previously
[29]. Patients C16 years of age with a diagnosis
of narcolepsy with cataplexy, based on clinical
history, an overnight polysomnogram, and
multiple sleep latency test, were randomized
to 8 weeks of treatment with placebo or with
SXB in doses of 4.5, 6, or 9 g, administered as
two equally divided nightly doses; the second
dose was taken 2.5–4 h after the first dose. For
patients receiving 6 and 9-g doses of SXB, the
doses were titrated in weekly 1.5-g increments.
The use of stable doses of stimulants for the
treatment of EDS was allowed.
Medical Outcomes Survey 36-Item Short
Form
To assess changes in HRQoL associated with
treatment, the Medical Outcomes Survey
SF-36 [33, 34] was administered during the
study as an exploratory efficacy endpoint. The
SF-36 is a widely used generic instrument for
evaluating HRQoL, consisting of eight
subscales evaluating specific health status
domains and two summary scales, a Physical
Component Summary (PCS) and a Mental
Component Summary (MCS). The domain
subscales include Physical Functioning
(ability to perform physical activity);
Role–Physical, which assesses the impact of
physical function on daily roles (work, daily
activities); Bodily Pain (presence of pain and
its impact on limiting activities); General
Health (GH; overall health status); Vitality
(energy and tiredness); Social Functioning
(ability to perform social activities);
Role–Emotional (impact of emotional
problems on participation in life activities
such as work and other daily activities); and
Mental Health (general mood, i.e., anxiety,
depression). The PCS is derived from
positively weighting the domains of Physical
Functioning, Role–Physical, Bodily Pain, and
GH, while the MCS weights the domains of
Vitality, Social Functioning, Role–Emotional,
and Mental Health. Scores on the SF-36 range
from 0 to 100, with higher scores indicating
better health status. Normative values for the
US population have been published [35], and
a change of five points is generally accepted as
the minimum clinically important difference
(MCID) [36].
Statistical Analyses
The SF-36 was administered at baseline and at
weeks 4 and 8, with efficacy measured as change
from baseline at the end of double-blind
treatment (week 8) using a
last-observation-carried-forward analysis on
the intent-to-treat population. Scores were
transformed to norm-based scoring using 1998
SF-36 US population norms [37].
Within-group change from baseline was
evaluated using a paired t test, and
differences in the change from baseline
between groups were evaluated using an
analysis of variance model with adjustment
for treatment and site. Pairwise comparisons
versus placebo were performed if the overall
p was less than 0.05. Effect sizes (ES) versus
placebo were estimated based on the difference
between the mean change from baseline in the
active treatment group and the mean change
in the placebo group divided by the pooled
standard deviation (SD) of the active and
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placebo treatment groups (Cohen’s d); ES of
0.20 are generally considered small, 0.50 are
moderate, and 0.80 are large [38].
Statistical analyses were performed using SAS
version 9 software (SAS Institute, Inc., Cary, NC,
USA).
Compliance with Ethics Guidelines
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. Informed consent was obtained from all
patients for inclusion in the study
(ClinicalTrials.gov identifier NCT00049803).
RESULTS
Demographics and Clinical Characteristics
Demographic characteristics of the
intent-to-treat population were similar across
the study groups (Table 1). Overall, patients
were predominantly female (65.4%) and white
(86.0%), with a mean ± SD age of
40.5 ± 15.3 years. The clinical characteristics of
narcolepsy in these patients were also similar
across groups, and showed that the population
was characterized by moderate-to-severe
disease. In particular, the mean Epworth
Sleepiness Scale (ESS) score ranged from 17.3
to 18.2 across treatment groups (scores C10 are
considered to represent clinically important
sleepiness [39]). Additionally, patients reported
the frequent occurrence of other narcolepsy
symptoms (Table 1). The mean values of all
SF-36 domains at baseline showed impaired
QoL (Table 1) and were not significantly
different across treatment groups, except for
the PCS (p = 0.040).
Changes from Baseline
Significant changes from baseline on the PCS
were observed with all SXB doses (p\0.05) but
not with placebo (Fig. 1). The 9-g dose resulted
in the greatest change (mean ± SD), 6.3 ± 9.1
points, which exceeded the MCID. This change
was also significantly greater relative to the
1.5 ± 6.2 points with placebo (p = 0.005), and
the difference demonstrated a moderate ES
(0.616). In contrast, only the SXB 6-g dose
resulted in a significant change from baseline
on the MCS, and none of the changes with SXB
was significant relative to placebo (Fig. 1).
Among the individual domains (Fig. 2), all
SXB doses resulted in significant changes from
baseline in Physical Functioning (p\0.05) and
Vitality (p\0.001), with the 9-g dose observed
to have greatest effect. The changes from
baseline in Vitality exceeded the MCID for all
SXB doses.
The 9-g dose also resulted in significant
changes from baseline on Role–Physical
(p\0.05), Bodily Pain (p\0.05), GH
(p\0.001), and Social Functioning (p\0.05),
with the changes of 6.4 and 6.8 exceeding the
MCID for Role–Physical and Social Functioning,
respectively (Fig. 2). A significant change from
baseline was observed with placebo only for
Role–Physical (p\0.05).
In pairwise comparisons, Vitality was the
only domain where all SXB doses showed
significant differences relative to placebo
(Fig. 2), and while the ES for the 4.5-g dose
was small, at 0.394, the ES for the 6.5 and 9-g
doses were moderate, at 0.518 and 0.728,
respectively. The SXB 4.5 and 6-g doses did
not show significant differences compared to
placebo for any of the other domains. However,
the mean ± SD change from baseline with the
9-g SXB dose was significantly greater than with
placebo in the domains of Physical Functioning
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Table 1 Baseline demographic and clinical characteristics









Gender, n (%) 0.582
Male 17 (28.8) 21 (32.8) 22 (37.9) 19 (40.4)
Female 42 (71.2) 43 (67.2) 36 (62.1) 28 (59.6)
Age, years, mean (SD) 40.8 (15.5) 41.8 (16.7) 39.2 (15.9) 39.9 (12.5) 0.822
Race, n (%) 0.306
White 54 (91.5) 50 (78.1) 49 (84.5) 43 (91.5)
Black 3 (5.1) 11 (17.2) 7 (12.1) 4 (8.5)
Other 2 (3.4) 3 (4.7) 2 (3.4) 0
ESS, mean (SD) 17.3 (3.7) 18.0 (4.0) 18.2 (3.0) 17.8 (4.0) 0.462
Narcolepsy symptom episodes per week, mean (SD)
Cataplexy attacks 18.9 (14.8) 38.0 (121.0) 26.5 (27.4) 25.6 (29.3) 0.408
Awakenings 28.0 (61.3) 19.2 (11.7) 32.5 (45.7) 23.3 (19.4) 0.362
Hypnagogic hallucinations 4.1 (4.8) 5.1 (8.0) 6.4 (7.4) 4.7 (6.0) 0.258
Sleep paralysis 2.9 (3.7) 2.9 (4.8) 5.3 (7.9) 3.7 (4.7) 0.052
Inadvertent naps/sleep
attacks
14.6 (9.1) 18.6 (15.7) 21.0 (11.9) 18.5 (17.7) 0.077
SF-36 Score, mean (SD)
Physical Component
Summary
42.2 (8.3)b 45.1 (8.5) 46.3 (9.0) 42.7 (8.9) 0.040
Mental Component
Summary
40.5 (10.6)b 42.7 (12.0) 38.5 (10.2) 40.6 (11.3) 0.236
Physical Functioning 44.5 (9.9)b 45.9 (10.8) 46.1 (8.0) 43.6 (10.9) 0.509
Role–Physical 34.7 (9.4)b 38.0 (11.4) 37.8 (11.1) 35.3 (11.3) 0.230
Bodily Pain 47.8 (10.6)b 50.6 (10.3) 50.9 (10.0) 49.3 (10.1) 0.348
General Health 43.0 (9.1)b 47.5 (10.0) 45.1 (11.4) 45.0 (9.7) 0.124
Vitality 37.4 (8.9)b 38.9 (10.8) 37.7 (8.9) 36.6 (10.6) 0.673
Social Functioning 34.3 (13.2)b 38.1 (12.8) 37.1 (11.7) 33.6 (13.9) 0.194
Role–Emotional 40.8 (13.4)b 45.8 (12.3) 39.9 (13.1) 41.7 (13.9) 0.065
Mental Health 46.2 (9.2)b 45.7 (11.6) 43.5 (10.2) 46.6 (10.5) 0.410
ESS Epworth Sleepiness Scale, SD standard deviation, SXB sodium oxybate
a Values are for the intent-to-treat population defined as patients who received at least one dose of study medication and
had baseline and post-baseline efficacy measurements
b n = 58
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(4.4 ± 9.2 vs. 1.0 ± 8.0; p = 0.016), GH
(3.1 ± 7.0 vs. 0.4 ± 6.8; p = 0.036), and Social
Functioning (6.8 ± 16.8 vs. 1.1 ± 9.6; p = 0.033;
Fig. 2); these differences resulted in small ES of
0.394, 0.395, and 0.417, respectively.
DISCUSSION
Dose-Dependent HRQoL Response
This study found that SXB treatment in patients
with narcolepsy was associated with improved
HRQoL in a dose-dependent manner, and that
the 9-g dose provided the greatest benefits.
Consistent with other studies [18–20, 22, 24],
these patients were characterized by impaired
HRQoL, as shown by baseline values across all
SF-36 domains that were lower than normative
SF-36 values for the US population [35]. SF-36
Fig. 1 Change from baseline at 8 weeks in SF-36 compo-
nent summary scores. Data are for the intent-to-treat
population using last observation carried forward; broken
horizontal line represents the minimum clinically impor-
tant difference (MCID)
Fig. 2 Change from baseline at 8 weeks in SF-36
domain scores. Data are for the intent-to-treat popula-
tion using last observation carried forward; broken
horizontal line represents the minimum clinically
important difference (MCID). PF Physical Functioning,
RP Role–Physical, BP Bodily Pain, GH General Health,
V Vitality, SF Social Functioning, RE Role–Emotional,
MH Mental Health
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domain scores were also generally lower than
those reported in most other narcolepsy studies
that used this measure [14, 18–24], indicating
greater impairment of HRQoL at baseline. In
these patients, the frequency of narcolepsy
symptoms and the high ESS scores are
consistent with moderate-to-severe narcolepsy.
Significant improvements with SXB relative
to placebo were observed on the PCS and in four
of the eight SF-36 subscales, including Physical
Functioning, GH, Vitality, and Social
Functioning. Notably, the greatest changes
from baseline with SXB were consistently
observed in the Vitality domain across all
doses, also exceeding the MCID by a five-point
change. This domain was also the only one that
showed statistically significant differences
compared to placebo for all SXB doses.
Vitality, which is interpreted as a measure of
energy and fatigue, is the subscale that is often
reported to have the lowest value among the
SF-36 domains in patients with narcolepsy as
well as in the general population [18, 22, 24].
Although fatigue has not been considered a core
symptom of narcolepsy, it is frequently reported
by patients with narcolepsy [40, 41].
The significant changes from baseline in the
SF-36 Role–Physical and Social Functioning
domains, which also exceeded the MCID and
were significantly greater relative to placebo, are
consistent with previously reported
improvements in functional outcomes with
SXB as measured by the FOSQ [32]. The SF-36
Role–Physical would be analogous to the General
Productivity domain on the FOSQ, and SF-36
Social Functioning would be analogous to the
FOSQ Social Outcomes; both FOSQ functional
outcomes showed dose-dependent
improvements for the 6-g and 9-g SXB doses
and large ES relative to placebo [32].
There were some improvements in MCS with
SXB, but these were not statistically
significantly different from placebo. This lack
of an effect may suggest that the MCS is more a
measure of mental health (i.e., anxiety/
depression) than cognitive function [41, 42]. It
should be noted that a previous analysis from
this study that used the FOSQ did report that
6-g and 9-g SXB doses were associated with
significantly greater improvements relative to
placebo in the Vigilance domain [32]. This
domain assesses the cognitive functions of
attention and concentration.
Limitations
Limitations of this study include the 8-week
study duration. This observational period may
not be long enough to capture changes in
patient-reported QoL outcomes that may be
associated with narcolepsy treatment [24].
Clinically meaningful changes in EDS and
cataplexy with SXB may require 2 months or
more, and a longer period is required to achieve
maximum response [43]. Another limitation is
that the SF-36 is a disease-independent
assessment, and while it may be appropriate
for an overall understanding of HRQoL in
patients with narcolepsy relative to other
populations, it may not be fully responsive to
changes in domains associated with narcolepsy
treatment effects. Consequently, a
disease-specific measure is needed that could
more sensitively capture changes in outcomes
that impact HRQoL in patients with this
disorder. Nevertheless, the results of the
current study showed improvements in several
SF-36 subscales at the 9-g/day dose of SXB.
Finally, the use of the generally accepted MCID
of five points to indicate clinically meaningful
improvements could be criticized, since the
MCID is likely to vary across conditions.
However, in the absence of disease-specific
values, this threshold provides a relative
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measure for interpreting the observed
improvements.
CONCLUSIONS
SXB appears to improve QoL measures in a
dose-dependent manner, with the largest
impact at the 9-g/night dose, which had a
significant effect on the Vitality, GH, and
Physical and Social Functioning domains of
the SF-36. Studies of longer duration may be
needed to more fully evaluate the effects of SXB
on HRQoL in patients with narcolepsy, and the
results reported here also highlight the need for
a narcolepsy-specific measure of HRQoL.
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